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Abstract
Prognosis for patients with brain metastasis remains poor. Whole brain radiation therapy is the
conventional treatment option; it can improve neurological symptoms, prevent and improve tumor
associated neurocognitive decline, and prevents death from neurologic causes. In addition to whole
brain radiation therapy, stereotactic radiosurgery, neurosurgery and chemotherapy also are used
in the management of brain metastases. Radiosensitizers are now currently being investigated as
potential treatment options. All of these treatment modalities carry a risk of central nervous
system (CNS) toxicity that can lead to neurocognitive impairment in long term survivors.
Neuropsychological testing and biomarkers are potential ways of measuring and better
understanding CNS toxicity. These tools may help optimize current therapies and develop new
treatments for these patients. This article will review the current management of brain metastases,
summarize the data on the CNS effects associated with brain metastases and whole brain radiation
therapy in these patients, discuss the use of neuropsychological tests as outcome measures in
clinical trials evaluating treatments for brain metastases, and give an overview of the potential of
biomarker development in brain metastases research.
Introduction
Brain metastases, the most common intracranial tumor
occurring in approximately 10–30% of adult cancer
patients and 6–10% of children with cancer, are a major
cause of morbidity and mortality [1]. The majority of
these tumors metastasize from lung carcinoma, breast car-
cinoma and melanoma. Patients often present with head-
aches, nausea and/or vomiting and seizures. Many
patients also suffer from some form of neurological and/
or neurocognitive impairment which can cause emotional
difficulties and affect quality of life. The prognosis for
these patients is poor and without therapeutic interven-
tion the natural course is one of progressive neurological
deterioration with a median survival time of one month
[2]. Patients treated with whole brain radiation therapy
(WBRT) have a median survival of 3–6 months [2-5]. The
addition of WBRT can relieve neurologic symptoms and
prevent death from neurological causes [6].
The best predictor of survival is the Radiation Therapy
Oncology Group (RTOG) recursive partitioning analysis
(RPA) (Table 1). It divides patients treated with WBRT
into three survival classes based on the status of primary
tumor control, presence of extracranial metastases,
Karnofsky Performance Status (KPS) and age [7]. It has
been shown to retain its prognostic value in patients
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receiving stereotactic radiosurgery (SRS) along with WBRT
[8] and when stratifying for different histologies [9,10].
Recently a new prognostic index, called the Graded Prog-
nostic Assessment (GPA) has been developed (Table 2)
[11]. The GPA uses the sum of scores from four factors:
age, KPS, number of CNS metastases, and extracranial dis-
ease status. This new index was designed to guide treat-
ment choice, rather than reflect treatment results. It is
semi-quantitative, uses the most current data from rand-
omized trials, and has been shown to be as prognostic as
the RPA.
Methods to increase the efficacy of treatment but limit
CNS toxicity are currently being investigated. To measure
the effectiveness of these emerging treatment modalities
various tools will need to be incorporated into clinical tri-
als. Neuropsychological testing and biomarkers are two
such useful tools that will assist in optimizing radiation
delivery methods and in evaluating agents that modify the
effects of radiation. Biomarkers and neuropsychological
testing also may aid in making earlier diagnoses, monitor-
ing disease progression, and determining prognosis. This
review will briefly summarize the current treatment
options available for brain metastases and will review the
literature on neuropsychological outcome measures and
biomarkers in this patient population.
Treatment options
Conventional treatment options for brain metastases
include whole brain radiation therapy (WBRT), neurosur-
gery, and stereotactic radiosurgery (SRS), or a combina-
tion of the three. Corticosteroids can be used to control
peritumoral edema and alleviate neurological symptoms
[12]. Chemotherapy traditionally has had a limited role
and radiosensitizers are currently being investigated.
Table 1: RTOG RPA classification for brain metastases and associated survival by class in patients treated with WBRT
Class Patient characteristics Median survival (months)
I KPS ≥ 70 7.1
Age < 65 years
Controlled primary tumor
No extracranial metastases
II KPS ≥ 70 4.2
One of the following:
Age ≥ 65
Uncontrolled or synchronous primary disease
Extracranial metastases
III KPS < 70 2.3
Abbreviations: RTOG = Radiation Therapy Oncology Group; RPA = recursive partitioning analysis; KPS = Karnofsky performance status.
Table 2: Graded prognostic assessment
Score
00 . 5 1 . 0
Age > 60 50–59 < 50
KPS < 70 70–80 90–100
No. of CNS metastases > 3 2–3 1
Extracranial metastases Present -- None
GPA Score Median Survival (months)
0 – 1 2.6
1.5 – 2.5 3.8
36 . 9
3.5 – 4 11
Abbreviations: KPS = Karnofsky Performance Status; CNS = central nervous system.Radiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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Whole brain radiation therapy
WBRT is considered the standard treatment option for
patients who present with multiple brain metastases. It
results in a median survival of 3–6 months [2-5], reduces
the recurrence rate of metastases, and prevents death from
neurological causes [6]. By controlling and improving
neurological symptoms, it improves quality of life in 75 to
85% of patients [4]. In addition, WBRT is used in patients
with metastases that impinge on important brain struc-
tures or are too numerous for either surgery or SRS to be
effective. WBRT is used in conjunction with surgery and
SRS and its combination has been shown to improve local
control [13]. WBRT is effective and, unlike surgery and
SRS, it treats both gross and microscopic disease. Table 3
lists the randomized trials that have been performed to
determine doses and fractionation schedules of radiation
for patients with brain metastases [4,14-20]. The results
from these studies showed that the differences in dose,
timing, and fractionation do not have a statistically signif-
icant difference in median survival. Currently the most
common radiation dose in the United States for brain
metastases is 30 Gy in ten 3 Gy fractions over two weeks.
Surgery
Surgical resection is used as a treatment option for
patients with a favorable prognosis, surgically assessable
metastases and who have minimal extracranial disease
[21]. In patients with tumor(s) elsewhere in the body
under control, the resection of one or more closely situ-
ated metastases can increase survival significantly. Four
randomized trials that have been completed to address
the role of surgical resection of brain metastases are sum-
marized in Table 4. Three of the trials demonstrated that
combining surgery and WBRT for patients with a single
metastasis significantly extends survival and improves
quality of life when compared to WBRT alone [22-24].
One of the randomized trials failed to show an increase in
survival or a benefit in quality of life [25]. However, in
this study the patients had lower KPS and a higher inci-
dence of extracranial disease which may have affected the
outcome. Overall these results support the position that
surgical treatment should be utilized in patients with lim-
ited extracranial disease and in those patients with good
performance status.
Stereotactic radiosurgery
SRS is an alternative to neurosurgery, in which multiple
convergent beams of high energy x-rays, gamma rays, or
protons are delivered to a discrete radiographically
defined treatment volume. SRS can be used to treat single
lesions or multiple lesions (usually up to 3) and can be
used to treat deep-seated surgically inaccessible lesions. It
has been shown in several large retrospective analyses to
be equivalent to surgery [8,26]. Results from one rand-
omized trial and several retrospective studies have shown
that when SRS is used after WBRT there is a survival bene-
fit as well as stabilization or improvement in KPS [8,27].
There is no clear consensus on the survival advantage of
using SRS followed by adjunct WBRT. A randomized trial
by Aoyama et al [28], comparing SRS alone to WBRT plus
SRS, did not demonstrate a survival difference in patients
with 1 to 4 brain metastases. In this study intracranial
relapse occurred more frequently in those who did not
receive WBRT [28]. In a phase II trial looking at patients
treated with SRS for renal cell carcinoma, melanoma, or
sarcoma found that there was a high degree of failures
within the brain (approximately 50% of patients by 6
months) with the omission of WBRT [29].
The role of WBRT after SRS remains unclear. Some inves-
tigators advocate the omission of WBRT after SRS because
SRS has excellent local tumor control for single metastasis
and withholding WBRT will spare the patient from the
neurocognitive deficits associated with WBRT. Others
argue that many patients initially treated with SRS either
have micrometastases or will develop recurrent brain
metastasis and thus should receive WBRT for local and
distant tumor control.
Table 3: Dose fractionation schedules of randomized trials of WBRT alone
Study (ref) Year n (Gy)/number of fractions Median Survival (months)
Harwood et al [14] 1977 101 30/10 vs 10/1 4.0–4.3
Kurtz et al [15] 1981 255 30/10 vs 50/20 3.9–4.2
Borgelt et al [4] 1980 138 10/1 vs 30/10 vs 40/20 4.2–4.8
Borgelt et al [16] 1981 64 12/2 vs 20/5 2.8–3.0
Chatani et al [17] 1986 70 30/10 vs 50/20 3.0–4.0
Haie-Meder et al [18] 1993 216 18/3 vs 36/6 or 43/13 4.2–5.3
Chatani et al [19] 1994 72 30/10 vs 50/20 or 20/5 2.4–4.3
Murray et al [20] 1997 445 54.4/34 vs 30/10 4.5
Survival differences between treatment arms were not significantly different in any study. Adapted from Shaw et al. [30]
Reprinted with permission from the American Society of Clinical Oncology.Radiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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Radiosensitizers and WBRT
Radiosensitizers are chemicals or biological agents that
increase the lethal effects of radiation on the tumor with-
out causing additional damage to normal tissue. Efaprox-
iral (RSR13) is one example of a radiosensitizer that has
shown some promise [30]. It is an allosteric modifier of
hemoglobin that works by decreasing the binding affinity
of hemoglobin to oxygen thus permitting greater oxygen-
ation of hypoxic tumor cells and enhancing the effect of
radiation. In addition to this example, other agents have
been investigated in clinical trials (Table 5) [30-37]. Over-
all these studies have produced mixed results, some have
shown a slight survival benefit, while the majority of stud-
ies have not shown a difference in survival. These results
have not been strong enough to bring any of these agents
into routine clinical care. At this time there are several
clinical trials underway involving other potential radio-
sensitizers http://www.clinicaltrials.gov.
Chemotherapy for brain metastases
The role of conventional chemotherapy has traditionally
been limited by the presence of the blood brain barrier
and by the potential resistance to chemotherapeutic
agents. Conventional chemotherapeutic agents include
topotecan, cisplatin, paclitaxel and temozolomide. Temo-
zolomide, a second-generation alkylating agent, has
100% bioavailability and readily crosses the blood-brain
barrier. Phase II results show that temozolomide is well
tolerated and gives an improvement in response rate [38].
Preclinical data has also shown that temozolomide could
be combined with radiation to enhance its effect [39].
Agents that are being currently investigated include gefit-
inib, lapatinib, valproic acid and thalidomide http://
www.clinicaltrials.gov. Future success of chemotherapy
will hinge on the development of new agents that have
improved penetration into CNS.
CNS effects of radiation therapy for brain 
metastases
WBRT, the standard of care for brain metastases, decreases
the tumor burden, which delays neurocognitive decline
and maintains quality of life. However, WBRT also can
cause brain injury and neurologic complications. There is
risk of dementia in long term survivors of brain metas-
tases treated with WBRT [40,41], which is thought to be
dependent on the total dose of radiation, the size of the
irradiated field, and the fraction size. Understanding and
measuring the neurotoxicity associated with WBRT as well
as SRS is important for evaluating different treatment reg-
imens beyond the effects on survival and time to disease
progression.
Pathophysiology of radiation induced CNS toxicity
Radiation predominantly causes vascular endothelial
damage and demyelination of white matter leading to
white matter necrosis [42]. Clinically, radiation injury of
Table 4: WBRT vs surgery plus WBRT in randomized trials
Study (ref) Year Treatment (Gy)/number of fractions n Median survival (mo) P Value
Patchell et al [22] 1990 Biopsy + WBRT 36 Gy/12 23 3.4 < 0.01
S + WBRT 25 9.2
Vecht et al [23] 1993 WBRT 40Gy/10 31 6 0.04
S + WBRT 32 10
Noordijk et al [24] 1994 WBRT 40Gy/10 34 6 0.04
S + WBRT 32 10
Mintz et al [25] 1996 WBRT 30Gy/10 43 6.3 0.24
S + WBRT 41 5.6
Abbreviation: S = Surgery
Table 5: Trials of WBRT plus radiation sensitizers for brain metastases
Study (ref) Year n Radioenhancer (Gy)/number of fractions Median Survival (months) WBRT + RS vs 
WBRT
Eyre et al. [31] 1984 111 metronidazole 30/10 3.0 vs 3.5
DeAngelis et al. [32] 1989 58 lonidamine 30/10 3.9 vs 5.4
Komarnicky et al. [33] 1991 779 misonidazole 30/6-10 3.9
Phillips et al. [34] 1995 72 BUdR 37.5/15 4.3 vs 6.1
Mehta et al. [35] 2003 401 motexafin gadolinium 30/20 5.2 vs 4.9
Shaw et al. [30] 2003 57 efaproxiral 30/10 7.3 vs 3.4
Suh et al. [36] 2006 515 efaproxiral 30/10 5.4 vs 4.4
Knisely et al. [37] 2008 183 thalidomide 37.5/15 3.9 vs 3.9
Abbreviations: RS = Radiation Sensitizer, BUdR = bromodeoxyuridineRadiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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the brain can be divided into three categories: acute, sub-
acute and late. Acute effects occur within the first few
weeks of radiation treatment and are likely caused by cer-
ebral edema and disruption of the blood brain barrier.
Symptoms include drowsiness, headache, nausea and
vomiting. Subacute encephalopathy occurs at one to six
months after the completion of radiation and its mecha-
nism of damage is believed to be due to diffuse demyeli-
nation. Symptoms, which resolve in several months,
include headache, somnolence, fatigability, and a tran-
sient impairment in cognitive functioning. Late effects are
seen six months after radiation and are usually due to
damage of the white matter tracts caused by injury to vas-
cular endothelial cells, axonal demyelination, and coagu-
lation necrosis. These late effects usually cause permanent
and progressive memory loss and can lead to severe
dementia [43].
The incidence of radiation induced dementia is not well
studied. The most commonly cited study is from a retro-
spective review of 47 patients who survived more than
one year treated with WBRT [41]. Five (11%) of those
patients were reported to develop severe radiation-
induced dementia at one year. However, four of these five
patients were treated with high radiation fractions (5 or 6
Gy) that are not routinely used. Another study by the
same authors reports an incidences of 1.9 to 5.1%, but
once again this retrospective review included patients
treated with unconventional fractions (4 – 5 Gy) [40].
Contrast enhancing CT findings in these patients reveal
cortical atrophy and hypodense white matter. Autopsies
on patients with severe radiation induced dementia reveal
diffuse chronic edema of hemispheric white matter in the
absence of tumor recurrence [40].
The pathophysiology of late radiation injury is a complex
process involving damage to oligodendrocytes, endothe-
lial cells, neurons, microglia and astrocytes and the deple-
tion of stem and progenitor cells. It also is a dynamic
process that involves recovery/repair responses with
release of various cytokines and the involvement of sec-
ondary reactive processes that result in persistent oxida-
tive stress [42].
Vascular damage leading to ischemia and consequently
white matter necrosis is thought to be a major mechanism
for late delayed neurocognitive impairment caused by
WBRT. This mechanism is supported by animal experi-
ments designed specifically to study the long-term cogni-
tive effects of rats treated with whole brain radiation.
Using this model, investigators found that loss of vessel
density appeared before cognitive impairment with no
other gross brain pathology being present, suggesting cog-
nitive impairment arose after brain capillary loss [44].
Damage to the subgranular zone of the hippocampal den-
tate gyrus also has been suggested as a mechanism of long
term radiation induced cognitive impairment. Recent ani-
mal experiments have shown that this area is extremely
sensitive to whole brain radiation [45]. Dosimetric plan-
ning for WBRT to spare the hippocampal region is already
underway [46].
Neuropsychological functioning of patients treated with 
radiation for brain metastases
For many patients with brain metastases, controlling neu-
rological symptoms, preventing cognitive dysfunction,
and maintaining functional independence are just as
important as prolonging survival. Multiple factors, how-
ever, may negatively impact the neurocognitive function-
ing of these patients including the presence of the tumor,
WBRT, SRS, neurosurgical procedures, chemotherapy, and
other drugs that have neurotoxic effects such as steroids
and anticonvulsants [47,48]. Research investigating the
effects of treatment, including WBRT, on the neurocogni-
tive functioning of patients with brain metastases is lim-
ited. While many studies have evaluated the
neurocognitive outcome of patients treated with radia-
tion, particularly children [49,50] and long term survivors
of gliomas [51,52], the data from these populations are
not directly comparable to patients undergoing WBRT
and/or SRS for brain metastases. To examine the neuro-
cognitive functioning of patients with brain metastases
treated with radiation, some studies used the Folstein
Mini-Mental State Examination (MMSE) [53] while more
recent trials administered a battery of neuropsychological
tests.
Neurocognitive impairments prior to radiation
Neurocognitive impairment in patients with brain metas-
tases is common prior to receiving radiation treatment. In
studies using the MMSE to assess neurocognitive status, 8
to 16% of patients were classified as having dementia [54-
56] prior to receiving radiotherapy. Lower MMSE scores at
baseline were associated with greater tumor volume
[54,57] and death [55].
Neuropsychological testing was used in a phase III rand-
omized trial to evaluate whether motexafin gadolinium
administered with WBRT could improve neurologic and
neurocognitive outcome and survival in patients with
brain metastases [35,58]. This trial administered a brief
battery of standardized neurocognitive tests assessing the
domains of memory, executive function, and motor speed
in 401 patients at study entry and at monthly intervals for
the first six months and every three months until death
[35,58]. Of these patients, 90.5% exhibited neurocogni-
tive impairment prior to beginning WBRT, with 42% of
the patients having impairment in at least four out of the
eight tests administered. Similarly, another study using a
neurocognitive test battery found that 67% of patientsRadiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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with one to three brain metastases were impaired on at
least one test and 50% were impaired on two or more tests
prior to radiation therapy [59]. In both of these trials,
domains of functioning that tended to be the most
impaired include fine motor dexterity, executive function,
and memory, particularly immediate and delayed recall.
The severity of neurocognitive impairment from brain
lesions generally is related to the size of the tumor rather
than the number of metastases. Meyers et al. [58] found
that the volume of the indicator lesion was highly corre-
lated with each neurocognitive test score at baseline. In
addition, Chang et al. [59] found that patients with tumor
volume greater than 3 cm3 had worse performance on a
measure of attention span.
Baseline neurocognitive function also is predictive of
overall survival [58]. Tests of memory, motor dexterity,
executive function, and global impairment were inde-
pendent predictors of survival. When analyzed with other
clinical parameters, impaired scores on the baseline Peg-
board dominant hand test (a measure of fine motor dex-
terity) were found to be predictive of survival in addition
to other factors such as male sex, number of brain metas-
tases, and low KPS.
Neurocognitive function after WBRT
In the phase III randomized trial noted above, Meyers et
al. [58] found that after treatment, overall neurocognitive
test scores declined over time as patients progressed, with
fine motor speed deteriorating the most (31% at 3
months) and verbal fluency the least (7% at 3 months).
Changes in neurocognitive test scores correlated signifi-
cantly with changes in tumor volume but not with the
number of metastases. Patients with progressive disease
showed greater deterioration in each neurocognitive func-
tion test compared to patients with partial response who
demonstrated stable or improved performance on some
tests. Furthermore, in a subset of patients with non-small-
cell lung cancer, a prolonged time-to-neurocognitive pro-
gression for memory and executive function was found in
patients treated with motexafin gadolinium and WBRT
compared to WBRT alone, despite no difference between
the two arms in overall survival or time to neurological or
neurocognitive progression [58]. Thus, differential effects
were found for specific neurocognitive functions support-
ing the use of neuropsychological testing in similar clini-
cal trials.
Based on the 208 patients who received WBRT alone in
the previously described phase III randomized trial [58],
Li et al [60] investigated the relationship between tumor
volume and neurocognitive function. Compared to poor
responders, good responders exhibiting tumor reduction
took longer to deteriorate in neurocognitive function on
all tests but particularly on measures of executive function
and fine motor speed. Similarly, tumor reduction corre-
lated significantly with improvement in executive func-
tion and fine motor speed but not with changes in
memory in a small sample of long-term survivors [60].
Thus, by reducing intracranial tumor burden, WBRT
improves certain aspects of cognition. However, WBRT
may have a specific negative effect on memory, which may
be related to damage to the hippocampus. Patients surviv-
ing over one year had a greater reduction in tumor volume
and better neurocognitive outcomes after WBRT than
patients only surviving to four months [60]. A consistent
finding from studies using either neuropsychological test-
ing [58,60] or the MMSE [54,57] indicates that tumor
control has a beneficial effect on neurocognitive function
and quality of life.
In a secondary analysis of a study designed to test the fea-
sibility of administering neuropsychological tests in brain
metastasis patients [61], investigators looked at the short-
term impact of WBRT on neurocognitive and quality of
life measures [62]. They administered neuropsychological
tests at baseline, the end of radiation therapy, and at one
month follow up. Although declines in tests scores
occurred immediately after radiation, improvements in
neurocognitive and quality of life measures were found at
one month post-WBRT compared to pre-WBRT, even in a
group with limited expected survival. At one month fol-
low up, the majority of patients exhibited improved or
stable performance compared to baseline in memory,
attention, and executive function. Li et al. [63], found that
six months after WBRT, neurocognitive function predicted
decline in QOL, as measured by activities of daily living,
with Delayed Recall (memory) being the most predictive
test. This finding suggests that delaying neurocognitive
deterioration is important for preserving patients' quality
of life. Since control of intracranial tumors, even for a
short period of time, is associated with stabilization and
improvement in neurocognitive function and quality of
life, the use of WBRT outweigh the long-term risks in these
patients [60].
Neurocognitive function after SRS
In a small pilot study evaluating neurocognitive function
in patients receiving SRS alone for the treatment of one to
three brain metastases [59], Chang et al. found that after
one month all 13 patients declined on at least one neuro-
cognitive test with about half showing decline on two or
more tests. Patient's scores declined most frequently on
tests of learning and memory (54%) and motor dexterity
(46%). On other tests measuring executive function,
attention, and verbal fluency, some patients exhibited
improvements in their scores while others declined. Five
patients were evaluated 200 days after their baseline eval-
uation to assess late cognitive effects. Stable or improved
functioning was found in learning and memory in fourRadiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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patients and in executive function and motor dexterity in
three patients. In this small study of long-term survivors
of brain metastases treated with SRS alone, the majority
demonstrated stable or improved neurocognitive func-
tioning.
Aoyama et al. [57] used the MMSE to assess patients in
their randomized trial evaluating SRS alone versus SRS
plus WBRT. Their results showed that patients who
received WBRT combined with SRS experienced a stable
MMSE score for approximately 2 years after treatment
compared with SRS alone. This is thought to be due to the
preventative effect of WBRT on brain tumor recurrence.
Currently, there is an ongoing randomized Phase III clin-
ical trial being run by the North Central Cancer Treatment
Group (NCT00377156) and supported by the National
Cancer Institute that does assess the neurocognitive effect
of receiving either SRS alone or SRS followed by adjuvant
WBRT in patients with three or fewer brain metastases.
The trial's primary endpoint is overall survival but its sec-
ondary endpoints will evaluate quality of life and neuro-
cognitive function by means of a battery of tests that
evaluate memory, fluency, executive function, and coordi-
nation.
Improving neurocognitive function after WBRT
Multiple pharmacological agents have been proposed and
are being investigated that could potentially improve cog-
nition, mood, and quality of life in patients receiving radi-
ation for brain tumors. These agents include
methylphenidate, alpha-tocopherol, pentoxifylline and
donepezil [64-67]. Currently there is an ongoing rand-
omized phase III trial (RTOG 0614), testing memantine
hydrochloride versus placebo in preventing cognitive dys-
function in patients undergoing WBRT for brain metas-
tases. Mematine is a NMDA-receptor antagonist used in
the treatment of Alzheimer disease. The study is using an
extensive battery of neuropsychological assessments and
quality of life measurements and is also collecting blood
and urine specimens for future studies.
The use of neuropsychological assessments
Neurocognitive function, which impacts quality of life
[63,68], is an important outcome measure in clinical trials
for cancer therapies. In some studies involving patients
with brain metastases, the Folstein MMSE [53] has been
used to assess neurocognitive function [54-57]. It is brief
test that was designed to assess delirium or significant
dementia. However, the MMSE does not adequately meas-
ure all the cognitive areas affected by radiation and is not
a sensitive tool for detecting cognitive impairment in
these patients [68,69] or changes related to therapeutic
interventions [69]. Only 50% of patients having impaired
cognitive function based on neuropsychological testing
were considered abnormal on the MMSE [70]. Further-
more, scores on the MMSE did not change despite a
decline in memory function assessed by neuropsycholog-
ical testing. Thus, short batteries of objective standardized
neuropsychological tests are recommended to assess cog-
nitive functioning in clinical trials of patients with brain
metastases.
Standardized neuropsychological tests are reliable and
valid measures that are sensitive to changes in central
nervous system function, and thus have been used as out-
come measures in clinical trials. When selecting neuropsy-
chological tests for use in clinical trials, several guidelines
should be followed [71]. First, tests should be selected to
assess the specific domains of functioning that may be
affected by treatment. Second, tests need to be re-admin-
istered repeatedly, thus it is best to have alternate forms or
tests that are more resistant to learning in order to mini-
mize practice effects. Finally, the tests should be standard-
ized measures with documented reliability and validity. In
addition to these general criteria, several other considera-
tions should be made when devising a test battery for use
in clinical trials of patients with brain metastases [61].
First, these patients have a shortened lifespan and may
feel fatigued, thus the test battery should be brief to facil-
itate compliance and lessen the burden on the patient.
Second, the cost of the tests and level of staff training
required to administer them should be considered, partic-
ularly for multi-center studies. Limited information is
available regarding the appropriate neuropsychological
tests to be used specifically in clinical trials for patients
with brain metastases. However, there needs to be valida-
tion and consensus of an appropriate neuropsychological
test battery for determining prognosis for treatment and
for comparing the results of future clinical trials.
Recently, a phase III randomized trial used a brief battery
of neuropsychological tests to generate more specific data
about the neurocognitive effects of brain metastases
before and after treatments [35,58,60,63]. These tests,
which evaluate memory, verbal function, fine motor coor-
dination, and executive function, provide a more accurate
and comprehensive measurement of neuropsychological
changes in patients with brain metastases who are treated
with radiation therapy [68,69]. This short battery has a
high compliance rate and can be completed in a reasona-
ble time in patients with brain metastases [61,68]. To fur-
ther develop neuropsychological testing for use in clinical
trials of patients with brain metastases, the National Can-
cer Institute (NCI) Radiation Oncology Branch adapted
the Meyers et al. [58,68] test battery by adding a few brief
measures specifically to assess processing speed, working
memory, and attention, which are functions that can be
affected by radiation [47]. In addition, a test of estimated
intelligence was included to serve as a measure of premor-Radiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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bid functioning. Besides these neuropsychological tests,
measures of quality of life and activities of daily living also
should be included in clinical trials to assess everyday
functioning [72]. Examples of two such measures are the
Barthel index and the Functional Assessment of Cancer
Therapy-Brain (FACT-Br), which previously have been
used in studies of patients with brain metastases[56,63].
The Barthel Index assesses daily living skills [73] and the
FACT-Br was developed specifically to address the quality
of life issues concerning brain tumor patients undergoing
treatment [74]. Table 6 lists the measures that were com-
piled for an NCI research protocol that will examine
which tests are sensitive to CNS changes in patients with
brain metastases receiving WBRT. These tests are standard-
ized, have alternate forms or are somewhat resistant to
practice effects, and assess the main domains that may be
affected by radiation. Furthermore, the battery takes less
than one hour to administer, most of the tests are rela-
tively inexpensive, and technicians can administer these
tests appropriately when trained and supervised by a psy-
chologist. The data generated from this protocol will be
considered with findings from other studies to propose a
standard neuropsychological test battery for use in the
clinical trials of these patients to facilitate the comparison
of different treatment regimens.
Ultimately, having a brief test battery that is reliable and
sensitive in detecting meaningful neuropsychological
change in this patient population is very important. In the
clinic, a condensed neuropsychological battery would be
useful in monitoring cognitive and behavioral changes
and predicting outcome. In research, a standardized neu-
ropsychological test battery is an essential tool that needs
to be incorporated into all future clinical trials investigat-
ing treatments for brain metastases. Such a battery should
be used when assessing new radiation methods or delivery
schemes and in trials investigating agents that modify
radiation.
Biomarkers as indicators of CNS injury
In addition to neuropsychological testing, biomarkers
may be a useful research and prognostic tool. Elevated lev-
els of certain proteins or neurotransmitters in the blood or
urine may be indicators of CNS damage caused by inva-
sion of brain metastases and/or radiation induced dam-
age. Much of the work on biomarkers for CNS injury has
been done in stroke patients. These studies have identified
multiple markers of blood brain barrier disruption and
neuronal damage. The various categories include markers
of endothelial damage, excitotoxicity, inflammation and
angiogenesis (Table 7).
Two serum markers that have potential as screening tools
for endothelial and neuronal damage are neuron-specific
enolase (NSE) and S100B. NSE is a glycolytic enzyme
found in the CNS, which is expressed by neural and neu-
roendocrine cells [75] and can be used as a marker of neu-
ronal damage. Elevated levels have been found in patients
with brain metastases from both small cell lung cancer
and non-small cell lung cancer (NSCLC) [76]. A multi-
center retrospective study involving 231 NSCLC patients
demonstrated that high serum levels of NSE indicated
shorter survival and was a specific marker of metastases
[77].
S100B is a nervous system specific cytoplasmic protein
found in astrocytes and is released into circulation when
the blood brain barrier is breached [78]. It is elevated in
stroke patients and its levels have been shown to corre-
spond to infarct volume [79]. In a study looking at the
presence of S100B in the serum of 38 patients with lung
carcinoma, an elevated S100B level was either associated
with brain metastases or with the presence of imaging
changes suggestive of chronic, diffuse cerebral microvas-
cular disease [80]. S-100 levels have also been shown to be
a predictive marker of melanoma brain metastases [81].
Table 6: Suggested neuropsychological test battery
Psychometric Test Domains Time (mins)
North American Adult Reading Test-35 [95] Estimated Intelligence 5
Hopkins Verbal Learning Test [96]
WAIS-III Digit Span subtest [97]
Memory 8 
5
Ruff 2 & 7 Selective Attention Test [98] Attention 5
WAIS-III Symbol Search subtest [97] Processing Speed 2
Trail Making Test A & B [99]
Controlled Oral Word Association Test [100]
Executive Function 5 
5
Grooved Pegboard [101] Motor Function 5
Barthel Index [73] Adaptive Function 5
Functional Assessment of Cancer Therapy – Brain [74] Quality of Life 5
Total Time 50 mins
Abbreviations: WAIS-III = Wechsler Adult Intelligence ScaleRadiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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Neuronal damage can lead to excitotoxicity where excess
neurotransmitters such as glutamate and GABA are
released. This increase in neurotransmitters causes an
influx of Ca2+ leading to Ca2+ mediated cell death [82].
Excitotoxicity is seen in traumatic brain injury, ischemic
stroke and neurodegenerative diseases. In addition, gluta-
mate and GABA have been measured in the blood of
patients who have had a stroke [83,84]. The release of
neurotransmitters has never been studied in patients with
brain metastasis or in patients with CNS damage caused
by radiation but they also may be potential markers.
Radiation stimulates the inflammatory pathway and leads
to the release of various cytokines, adhesion molecules
and chemokines. Animal models have shown that radia-
tion induced damage to the brain up regulates expression
of TNF alpha, ICAM-1 and Il-1 [85]. These inflammatory
markers already have been detected in the blood of
patients who received radiation [86]. Radiation as well as
CNS injury of any kind can cause release of these inflam-
mation molecules. For example TNF alpha, ICAM and Il-
1 all have been measured in the plasma of patients with
stroke induced brain injury [87,88]. These never have
been measured in patients receiving WBRT but they may
be potential markers of CNS damage.
Angiogenic proteins released by metastatic cancer cells
also may be used to monitor disease status and assist in
predicting recurrence. Angiogenic factors have been inves-
tigated as possible tumor markers in various malignancies
[89]. Vascular endothelial growth factor (VEGF) and
matrix metalloproteinases (MMPs) have been shown to
have prognostic value in various tumor types. A number
of studies have demonstrated the role of VEGF and MMPs
in breast [90], lung [91,92] and melanoma [93] metas-
tases, but none specifically have examined blood or urine
levels in patients with brain metastases. MMPs are not
only involved in tumor invasion but can also be a sign of
CNS vascular injury as indicated by an increase in plasma
levels of MMP9 and MMP13 in stroke patients [94].
The NCI Radiation Oncology Branch protocol mentioned
above that evaluates neuropsychological function also
includes the collection of serum, plasma and urine speci-
mens. The objective is to identify and evaluate the above
biomarkers and to investigate the ability of these biomar-
kers to predict neuropsychological decline after WBRT
and to predict progression of disease. The study will col-
lect specimens before WBRT, at the completion of WBRT,
and then at monthly intervals each coinciding with neu-
ropsychological testing.
Conclusion
WBRT is the standard of care in patients with brain metas-
tases with surgery and SRS playing an important role
when there are limited metastases. There are risks of neu-
rocognitive impairment associated with WBRT; however
omitting WBRT has been shown to be more detrimental
in terms of survival and neurocognitive outcomes. It is
also important to recognize that many patients present
with neurocognitive deficits even before beginning radio-
therapy. Many potential therapies being investigated also
carry a risk of neurocognitive decline and the current focus
of brain metastases research is to find ways to optimize
the therapeutic index. Future clinical trials will be
designed to answer questions such as the role of omitting
upfront WBRT and giving SRS alone for a single metasta-
sis, the benefit of administering prophylactic cranial irra-
diation to highly metastatic cancers such as HER2+ breast
cancer patients, the value of using hippocampal sparing
techniques, and the addition of radiosensitizers to
enhance WBRT. To answer these questions and evaluate
various treatment regimens that may have minimal differ-
ential effects on survival and disease progression, it is
important to assess other patient outcomes [72], espe-
cially functions affected by neurotoxicity. Thus, tests of
neuropsychological functioning should be included as
standard outcome measures in all of these future studies.
The challenge is finding a brief but sensitive and compre-
hensive test battery to assess the neurocognitive effects of
brain metastases and treatments.
Biomarkers have potential in clinical research involving
patients with brain metastases and are an avenue that
needs to be explored. They may have diagnostic potential
as well as potential for monitoring disease progression.
Markers found in the blood may aid in understanding the
pathophysiology of radiation induced CNS injury and
Table 7: Biomarkers of CNS injury
Excitotoxicity Glutamate GABA
GABA
Endothelial Damage Protein S100B
NSE
MMP-9
MMP-13
Inflammation TNF-alpha
Il-1
ICAM-1
VCAM-1
Angiogenesis MMP2
MMP9
VEGF
Abbreviations: NSE = neuron-specific enolase, MMP = matrix 
metalloproteinases
TNF = Tumor necrosis factor; Il = interleukin, ICAM = intercellular 
adhesion molecule; VCAM = vascular cellular adhesion molecule, 
VEGF = vascular endothelial growth factorRadiation Oncology 2008, 3:26 http://www.ro-journal.com/content/3/1/26
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assist in finding ways to target tumor cells while sparing
healthy cells. In clinical trials involving radiomodifiers,
biomarkers may be used to monitor the toxicity and effec-
tiveness of these agents. Biomarkers may also have a role
in predicting a decline in neurocognitive function. Ulti-
mately, combining the outcomes of neuropsychological
testing, biomarkers and imaging will help us improve the
management of these patients.
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